首页 › 基金 › Consolidated Portfolio Review Corp › ROIV
Consolidated Portfolio Review Corp 对 ROIV 的持仓历史
ROIVANT SCIENCES LTD · 医疗保健
Consolidated Portfolio Review Corp 在 Q3 2026 的 13F 申报中披露持有 ROIV(ROIVANT SCIENCES LTD)276,530 股,市值约 US$10.1M,约占其申报组合的 0.82%,在其申报持仓中市值排名第 18 位。 Consolidated Portfolio Review Corp 最近 4 个申报季度中有 4 个季度披露了 ROIV 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Consolidated Portfolio Review Corp 对 ROIV 的持仓演变
Consolidated Portfolio Review Corp 于 Q4 2025 首次披露 ROIV 持仓:276,530 股(约 US$6.0M)。 该持仓在 Q3 2026 达到峰值 276,530 股,市值约 US$10.1M。 在 4 次申报中,Consolidated Portfolio Review Corp 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 276,530 股、市值约 US$10.1M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 276.53K | $6.00M | 新进 |
| Q1 2026 | 276.53K | $7.66M | 持有 |
| Q2 2026 | 276.53K | $9.79M | 持有 |
| Q3 2026 | 276.53K | $10.11M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ROIV 与 13F 数据
ROIV(ROIVANT SCIENCES LTD)属于医疗保健行业。我们追踪的基金中还有 62 只申报持有 ROIV,申报仓位最大的包括:QVT Financial LP (US$839.6M), 法拉龙资本管理 (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ROIV 的基金
- QVT Financial LP 23.72M 股 · $839.56M · Q2 2026
- 法拉龙资本管理 14.31M 股 · $506.40M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.31M 股 · $506.40M · Q2 2026
- ADAGE CAPITAL PARTNERS GP, L.L.C. 10.35M 股 · $366.26M · Q2 2026
- PERCEPTIVE ADVISORS LLC 8.09M 股 · $286.14M · Q2 2026
- Patient Square Capital LP 7.71M 股 · $281.99M · Q3 2026
- Darwin Global Management, Ltd. 6.75M 股 · $234.33M · Q2 2026
- Rubric Capital Management LP 6.00M 股 · $212.34M · Q2 2026
- BAKER BROS. ADVISORS LP 4.72M 股 · $166.93M · Q2 2026
- Affinity Asset Advisors, LLC 3.75M 股 · $132.71M · Q2 2026
- ADAR1 Capital Management, LLC 3.16M 股 · $111.73M · Q2 2026
- Maverick 资本 2.83M 股 · $100.12M · Q2 2026
更多关于 Consolidated Portfolio Review Corp
常见问题
How long has Consolidated Portfolio Review Corp held ROIV?
Consolidated Portfolio Review Corp has disclosed ROIV holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Consolidated Portfolio Review Corp's current position in ROIV?
As of Q3 2026, Consolidated Portfolio Review Corp holds 276.53K shares of ROIV (ROIVANT SCIENCES LTD), valued at $10.11M, representing 0.82% of its reported portfolio and ranking #18.
Has Consolidated Portfolio Review Corp been buying or selling ROIV?
In the latest 13F filing (Q3 2026), Consolidated Portfolio Review Corp held unchanged its position in ROIV. The position peaked in Q3 2026 at 276.53K shares.
Which other funds hold ROIV?
Other major institutional holders of ROIV include QVT Financial LP, 法拉龙资本管理, FARALLON CAPITAL MANAGEMENT, L.L.C., among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.